

Cancer is a disease of mutations.

Cancer is caused by the changes in our genes that control the way our cells function. The cells in our body constantly evolve and sometimes mutate in a way that can be harmful to us. Endeavor is looking at a specific cancer mutation called PTCH-1 and is developing a drug meant to benefit patients with that mutation.


What is PTCH-1 LOF?

Some advanced solid tumors are known to have a gene mutation that results in the loss of function of a specific protein known as PTCH-1.

PTCH-1 is a tumor suppressor gene/protein in the Sonic Hedgehog pathway. The study drug, ENV-101, acts on a protein that is thought to be involved with the growth of these abnormal cells caused by a mutation of the PTCH-1 gene. By blocking this process, ENV-101 may slow the progress of the disease and may result in a partial or complete response.

Scan the QR code below to learn more about our Study on ClinicalTrials.gov

NCT05199584



Stay in Touch with Us



@EndeavorBioMed



[linkedin.com/endeavor-biomedicines](https://www.linkedin.com/company/endeavor-biomedicines)

EBMClinical@endeavorbiomedicines.com

(858) 727-3199

www.endeavorbiomedicines.com



ENDEAVOR
to **Improve Lives**

A Study Evaluating
the Safety and Efficacy of
ENV-101 (Taladegib)
in Patients with Advanced
Solid Tumors Harboring PTCH-1
Loss of Function Mutations

ENV-101

ENV-101 is a small molecule Hedgehog signaling inhibitor that is being developed as a precision therapy in multiple types of cancer where the Hedgehog pathway is implicated as a driver of the disease.

Six completed studies have characterized the pharmaceutical properties, including PK/PD in patients with advanced solid tumors and demonstrated a manageable safety profile.

Scan the QR code below to learn more about ENV-101 for PTCH-1 LOF cancer treatment.



Clinical Trials

We are developing ENV-101 for patients with tumor mutations in the Hedgehog pathway, which affect approximately 2% of all cancers. Mutations in this pathway can aberrantly activate downstream signaling resulting in proliferation, survival, and metastasis of cancer cells. ENV-101 may potentially inhibit the activity of the Hedgehog pathway, which may have a significant benefit on the lives of cancer patients with these mutations.

Who can participate?

- Any person 18 years or older.
- Any person who has a PTCH-1 LOF mutation.
- Any person who has an advanced solid tumor.

xCures Partnership

Endeavor is partnered with xCures. Regardless of your eligibility for the Endeavor trial, xCures will still send you a list of other treatment options that could work for your cancer mutation. This means that even if you are not eligible for the Endeavor trial, you will receive a list of other treatment options that could work against your cancer mutation.

How can I help if I can't participate?

Spread the word. If you have a family member/friend who you think may qualify for this trial, reach out.

The xCures logo, featuring a stylized 'x' in blue and 'Cures' in black, positioned in the bottom right corner of the page. The background of the entire page features a light blue DNA double helix graphic.